These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 19460067)

  • 1. The treatment of challenging behaviour in intellectual disabilities: cost-effectiveness analysis.
    Romeo R; Knapp M; Tyrer P; Crawford M; Oliver-Africano P
    J Intellect Disabil Res; 2009 Jul; 53(7):633-43. PubMed ID: 19460067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroleptics in the treatment of aggressive challenging behaviour for people with intellectual disabilities: a randomised controlled trial (NACHBID).
    Tyrer P; Oliver-Africano P; Romeo R; Knapp M; Dickens S; Bouras N; Ahmed Z; Cooray S; Deb S; Murphy D; Hare M; Meade M; Reece B; Kramo K; Bhaumik S; Harley D; Regan A; Thomas D; Rao B; Karatela S; Lenôtre L; Watson J; Soni A; Crawford M; Eliahoo J; North B
    Health Technol Assess; 2009 Apr; 13(21):iii-iv, ix-xi, 1-54. PubMed ID: 19397849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomised controlled trial.
    Tyrer P; Oliver-Africano PC; Ahmed Z; Bouras N; Cooray S; Deb S; Murphy D; Hare M; Meade M; Reece B; Kramo K; Bhaumik S; Harley D; Regan A; Thomas D; Rao B; North B; Eliahoo J; Karatela S; Soni A; Crawford M
    Lancet; 2008 Jan; 371(9606):57-63. PubMed ID: 18177776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of antipsychotic therapy in a naturalistic setting: a comparison between risperidone, perphenazine, and haloperidol.
    Coley KC; Carter CS; DaPos SV; Maxwell R; Wilson JW; Branch RA
    J Clin Psychiatry; 1999 Dec; 60(12):850-6. PubMed ID: 10665632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overcoming the barriers experienced in conducting a medication trial in adults with aggressive challenging behaviour and intellectual disabilities.
    Oliver-Africano P; Dickens S; Ahmed Z; Bouras N; Cooray S; Deb S; Knapp M; Hare M; Meade M; Reece B; Bhaumik S; Harley D; Piachaud J; Regan A; Ade Thomas D; Karatela S; Rao B; Dzendrowskyj T; Lenôtre L; Watson J; Tyrer P
    J Intellect Disabil Res; 2010 Jan; 54(1):17-25. PubMed ID: 19627427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol.
    Chouinard G; Albright PS
    J Clin Psychopharmacol; 1997 Aug; 17(4):298-307. PubMed ID: 9241010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Cost-effectiveness Analysis of Antipsychotics for Treatment of Schizophrenia in Uganda.
    Lubinga SJ; Mutamba BB; Nganizi A; Babigumira JB
    Appl Health Econ Health Policy; 2015 Oct; 13(5):493-506. PubMed ID: 25958192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing a drug's cost-benefits.
    Raleigh F
    Psychiatr Serv; 1996 Aug; 47(8):877-8. PubMed ID: 8837167
    [No Abstract]   [Full Text] [Related]  

  • 10. Olanzapine: an updated review of its use in the management of schizophrenia.
    Bhana N; Foster RH; Olney R; Plosker GL
    Drugs; 2001; 61(1):111-61. PubMed ID: 11217867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risperidone: new indication. Behavioural disorders in children with autism or mental disabilities: no progress.
    Prescrire Int; 2006 Apr; 15(82):43-5. PubMed ID: 16602211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aggression Following Traumatic brain injury: Effectiveness of Risperidone (AFTER): study protocol for a feasibility randomised controlled trial.
    Deb S; Leeson V; Aimola L; Bodani M; Li L; Weaver T; Sharp D; Crawford M
    Trials; 2018 Jun; 19(1):325. PubMed ID: 29929537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia.
    Bounthavong M; Okamoto MP
    J Eval Clin Pract; 2007 Jun; 13(3):453-60. PubMed ID: 17518814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic evaluation of antipsychotic drugs for schizophrenia treatment within the Brazilian Healthcare System.
    Lindner LM; Marasciulo AC; Farias MR; Grohs GE
    Rev Saude Publica; 2009 Aug; 43 Suppl 1():62-9. PubMed ID: 19669066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population.
    Gibson PJ; Damler R; Jackson EA; Wilder T; Ramsey JL
    Value Health; 2004; 7(1):22-35. PubMed ID: 14720128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis.
    De Graeve D; Smet A; Mehnert A; Caleo S; Miadi-Fargier H; Mosqueda GJ; Lecompte D; Peuskens J
    Pharmacoeconomics; 2005; 23 Suppl 1():35-47. PubMed ID: 16416760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risperidone versus haloperidol: II. Cost-effectiveness.
    Davies A; Langley PC; Keks NA; Catts SV; Lambert T; Schweitzer I
    Clin Ther; 1998; 20(1):196-213. PubMed ID: 9522115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot randomised controlled trial of community-led ANtipsychotic Drug REduction for Adults with Learning Disabilities.
    McNamara R; Randell E; Gillespie D; Wood F; Felce D; Romeo R; Angel L; Espinasse A; Hood K; Davies A; Meek A; Addison K; Jones G; Deslandes P; Allen D; Knapp M; Thapar A; Kerr M
    Health Technol Assess; 2017 Aug; 21(47):1-92. PubMed ID: 28857740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Future employability, a new approach to cost-effectiveness analysis of antipsychotic therapy.
    Ganguly R; Miller LS; Martin BC
    Schizophr Res; 2003 Sep; 63(1-2):111-9. PubMed ID: 12892865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol.
    Kongsakon R; Leelahanaj T; Price N; Birinyi-Strachan L; Davey P
    J Med Assoc Thai; 2005 Sep; 88(9):1267-77. PubMed ID: 16536115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.